company background image
A1V

Aptorum Group DB:A1V Stock Report

Last Price

€1.47

Market Cap

€54.1m

7D

8.9%

1Y

-27.9%

Updated

06 Aug, 2022

Data

Company Financials +
A1V fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

A1V Stock Overview

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer.

Aptorum Group Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Aptorum Group
Historical stock prices
Current Share PriceUS$1.47
52 Week HighUS$2.28
52 Week LowUS$0.86
Beta0.066
1 Month Change18.55%
3 Month Change66.10%
1 Year Change-27.94%
3 Year Changen/a
5 Year Changen/a
Change since IPO-89.50%

Recent News & Updates

Shareholder Returns

A1VDE BiotechsDE Market
7D8.9%-2.5%1.1%
1Y-27.9%-2.0%-20.0%

Return vs Industry: A1V underperformed the German Biotechs industry which returned -2% over the past year.

Return vs Market: A1V underperformed the German Market which returned -20% over the past year.

Price Volatility

Is A1V's price volatile compared to industry and market?
A1V volatility
A1V Average Weekly Movement9.8%
Biotechs Industry Average Movement8.7%
Market Average Movement5.7%
10% most volatile stocks in DE Market10.7%
10% least volatile stocks in DE Market2.8%

Stable Share Price: A1V is more volatile than 75% of German stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: A1V's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
201026Darren Luihttps://www.aptorumgroup.com

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity.

Aptorum Group Fundamentals Summary

How do Aptorum Group's earnings and revenue compare to its market cap?
A1V fundamental statistics
Market CapUS$54.98m
Earnings (TTM)-US$25.05m
Revenue (TTM)US$1.54m

35.7x

P/S Ratio

-2.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
A1V income statement (TTM)
RevenueUS$1.54m
Cost of RevenueUS$1.46m
Gross ProfitUS$81.85k
Other ExpensesUS$25.13m
Earnings-US$25.05m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.70
Gross Margin5.31%
Net Profit Margin-1,624.64%
Debt/Equity Ratio0%

How did A1V perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is A1V undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A1V?

Other financial metrics that can be useful for relative valuation.

A1V key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue26.4x
Enterprise Value/EBITDA-2.3x
PEG Ration/a

Price to Sales Ratio vs Peers

How does A1V's PS Ratio compare to its peers?

A1V PS Ratio vs Peers
The above table shows the PS ratio for A1V vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average11x
PA8 Paion
9.4x49.7%€66.8m
MDG1 Medigene
5.8x-9.7%€60.9m
2INV 2invest
26.8xn/a€53.3m
VSCA 4SC
1.9xn/a€26.9m
A1V Aptorum Group
35.7x57.0%€55.0m

Price-To-Sales vs Peers: A1V is expensive based on its Price-To-Sales Ratio (35.7x) compared to the peer average (11x).


Price to Earnings Ratio vs Industry

How does A1V's PE Ratio compare vs other companies in the European Biotechs Industry?

Price-To-Sales vs Industry: A1V is expensive based on its Price-To-Sales Ratio (35.7x) compared to the German Biotechs industry average (5.8x)


Price to Sales Ratio vs Fair Ratio

What is A1V's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A1V PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio35.7x
Fair PS Ratio7.5x

Price-To-Sales vs Fair Ratio: A1V is expensive based on its Price-To-Sales Ratio (35.7x) compared to the estimated Fair Price-To-Sales Ratio (7.5x).


Share Price vs Fair Value

What is the Fair Price of A1V when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A1V (€1.47) is trading below our estimate of fair value (€38.07)

Significantly Below Fair Value: A1V is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Aptorum Group forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


56.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: A1V is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.01%).

Earnings vs Market: A1V is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: A1V is expected to become profitable in the next 3 years.

Revenue vs Market: A1V's revenue (57% per year) is forecast to grow faster than the German market (4.7% per year).

High Growth Revenue: A1V's revenue (57% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if A1V's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Aptorum Group performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-8.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: A1V is currently unprofitable.

Growing Profit Margin: A1V is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: A1V is unprofitable, and losses have increased over the past 5 years at a rate of 8.9% per year.

Accelerating Growth: Unable to compare A1V's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A1V is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.2%).


Return on Equity

High ROE: A1V has a negative Return on Equity (-154.88%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Aptorum Group's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: A1V's short term assets ($12.7M) exceed its short term liabilities ($4.4M).

Long Term Liabilities: A1V's short term assets ($12.7M) exceed its long term liabilities ($23.9K).


Debt to Equity History and Analysis

Debt Level: A1V is debt free.

Reducing Debt: A1V has no debt compared to 5 years ago when its debt to equity ratio was 0.01%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: A1V has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: A1V has less than a year of cash runway if free cash flow continues to reduce at historical rates of 9.8% each year


Discover healthy companies

Dividend

What is Aptorum Group current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate A1V's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate A1V's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if A1V's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if A1V's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as A1V has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Darren Lui (40 yo)

0.17

Tenure

US$512,115

Compensation

Mr. Darren Lui serves as Executive Director at Aptorum Group Limited since 2022 and also served as President since October 1, 2017 until June 01, 2022 and serves as its Chief Executive Officer since June 0...


CEO Compensation Analysis

Compensation vs Market: Darren's total compensation ($USD512.12K) is about average for companies of similar size in the German market ($USD426.57K).

Compensation vs Earnings: Darren's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: A1V's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: A1V's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.4%.


Top Shareholders

Company Information

Aptorum Group Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Aptorum Group Limited
  • Ticker: A1V
  • Exchange: DB
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$54.983m
  • Listing Market Cap: US$54.136m
  • Shares outstanding: 35.70m
  • Website: https://www.aptorumgroup.com

Number of Employees


Location

  • Aptorum Group Limited
  • 17 Hanover Square
  • London
  • Greater London
  • W1S 1BN
  • United Kingdom

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/06 00:00
End of Day Share Price2022/08/05 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.